June 01, 2026
4 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Switch from mepolizumab/benralizumab to depemokimab safe in severe asthma
ORLANDO — Both patients with asthma who switched from mepolizumab/benralizumab to depemokimab and patients who continued mepolizumab/benralizumab had low annualized exacerbation rates, according to results presented here. Depemokimab (Exdensur, GSK) is given twice a year since it is the first ultra-long-acting anti-IL-5 therapy, according to the presentation given at the American
1,152 words~5 min read
